Protein Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (Protein Sequencing Products, Reagents & Consumables, Instruments, Software, Protein Sequencing Services), By Application (Bio-therapeutics, Genetic Engineering, Others), By End Use (Academic Institutes & Research Centers, Pharmaceutical & Biotechnology, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.69 Billion
CAGR (2026-2031)	8.45%
Fastest Growing Segment	Protein Sequencing Services
Largest Market	North America
Market Size (2031)	USD 2.75 Billion

Market Overview

The Global Protein Sequencing Market will grow from USD 1.69 Billion in 2025 to USD 2.75 Billion by 2031 at a 8.45% CAGR. Protein sequencing involves determining the specific amino acid arrangement within a protein to understand its structure and function. The market is primarily driven by the expanding role of proteomics in drug discovery and the increasing demand for personalized medicine treatments. This growth is further supported by the rising incidence of chronic diseases which necessitates the identification of novel biomarkers for early diagnosis and therapeutic monitoring. According to the American Cancer Society, in 2024, the United States is projected to record over 2 million new cancer cases for the first time, underscoring the critical need for advanced proteomic profiling in oncology.

Nevertheless, the sector faces a significant challenge regarding the high cost and technical complexity of sequencing instrumentation. Unlike genomic material, proteins cannot be amplified, necessitating expensive and high-sensitivity equipment to detect low-abundance molecules effectively. This substantial financial burden, combined with a global scarcity of skilled bioinformaticians capable of interpreting complex proteomic data, restricts broader adoption among smaller research laboratories and impedes the rapid scalability of these technologies.

Key Market Drivers

Rising public and private investments in proteomics research act as a primary catalyst for the market, enabling the transition of high-sensitivity sequencing platforms from conceptual prototypes to commercial realities. This influx of capital allows emerging biotechnology firms to overcome the high barriers to entry associated with instrumentation costs and to scale their manufacturing capabilities. According to Alamar Biosciences, February 2024, in the 'Alamar Biosciences Closes $128 Million Series C Financing' press release, the company secured this capital to accelerate the commercialization of its automated proteomics platform, illustrating the strong investor confidence in next-generation protein analysis. This financial momentum further fosters a consolidating market environment where companies can sustain operations despite the capital-intensive nature of the technology; according to Standard BioTools Inc., January 2024, in the 'Standard BioTools Completes Merger with SomaLogic' press release, the combined entity reported a pro forma full-year 2023 revenue of approximately $180 million, reflecting the substantial economic scale currently operating within the sector.

The integration of artificial intelligence and bioinformatics in proteomic analysis serves as the second vital driver, addressing the critical bottleneck of data interpretation in complex sequencing workflows. AI algorithms are becoming indispensable for de novo sequencing and identifying post-translational modifications with speed and accuracy, tasks that previously required prohibitive amounts of manual analysis. These computational advancements are directly influencing pharmaceutical strategies, leading to high-value collaborations centered on AI-driven discovery. According to Eli Lilly and Company, January 2024, in the 'Lilly enters into strategic collaboration with Isomorphic Labs' announcement, the corporation agreed to an upfront payment of $45 million to leverage AI technologies for multi-target drug discovery, signaling a massive shift toward computational reliance in proteomics. By automating the analysis of intricate datasets, these technologies reduce the dependency on specialized bioinformaticians and streamline the path from protein sequencing to therapeutic target validation.

Download Free Sample Report

Key Market Challenges

The high cost and technical complexity of sequencing instrumentation present a significant hurdle to the growth of the Global Protein Sequencing Market. Unlike genomic material, proteins cannot be amplified, which necessitates the use of high-sensitivity equipment to detect low-abundance molecules effectively. This requirement leads to elevated equipment costs that create a steep barrier to entry for many potential users. Consequently, the adoption of these technologies is often limited to large institutions, leaving smaller research laboratories unable to afford the necessary capital investment.

This restriction is particularly damaging given the composition of the wider sector. According to MedTech Europe, in 2024, small and medium-sized companies constituted approximately 90% of the medical technology industry. Since the majority of the market comprises these smaller entities with limited budgets, the high cost of instrumentation directly impedes the rapid scalability and broader integration of protein sequencing. Furthermore, the scarcity of skilled bioinformaticians capable of interpreting the complex data generated creates an operational bottleneck, further discouraging adoption among laboratories that lack the resources to attract such specialized personnel.

Key Market Trends

The shift toward semiconductor-based sequencing chips is revolutionizing the sector by enabling single-molecule protein detection without the need for complex optical systems or amplification. This technological evolution allows for the direct reading of amino acid sequences on solid-state devices, significantly reducing the footprint and cost of analysis while enhancing sensitivity for low-abundance proteins. The commercial viability of this approach is becoming increasingly evident as early adopters integrate these platforms into standard workflows to bypass the technical limitations of traditional bulk methods. According to Quantum-Si, March 2025, in the 'Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results' press release, the company recorded a full-year revenue of $3.1 million, representing a 183% increase year-over-year, which demonstrates the rapidly growing market demand for these semiconductor-based proteomic solutions.

The convergence of protein sequencing with multiomics research is simultaneously reshaping experimental designs, as stakeholders seek to correlate genomic data with phenotypic proteomic expressions. This trend is driving the development of integrated workflows that allow the interrogation of DNA and proteins at a population scale, facilitating a more holistic understanding of disease mechanisms. Large-scale biobanking initiatives are currently spearheading this integration to create comprehensive biological datasets that support high-throughput drug discovery and biomarker validation. According to Illumina, Inc., January 2025, in the 'Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples' press release, the corporation initiated a study to generate next-generation sequencing-based proteomics data for 50,000 individuals, illustrating the massive scale at which multiomics integration is now being pursued.

Segmental Insights

The Protein Sequencing Services segment is anticipated to emerge as the fastest growing category in the Global Protein Sequencing Market due to a significant shift toward outsourcing laboratory operations. Pharmaceutical and biotechnology enterprises are increasingly utilizing third-party providers to avoid the substantial capital investment required for internal infrastructure and maintenance. Additionally, the need for adherence to rigorous characterization standards set by regulatory bodies such as the U.S. FDA drives demand for specialized external expertise. This strategic reliance allows organizations to access advanced analytical capabilities without managing the operational complexities of in-house sequencing facilities.

Regional Insights

North America maintains a leading position in the global protein sequencing market, driven by significant investments in pharmaceutical and biotechnology research. The region benefits from extensive funding for proteomics and precision medicine initiatives provided by established entities such as the National Institutes of Health. Additionally, the strong focus on drug discovery and development necessitates precise protein analysis to meet regulatory standards set by agencies like the US Food and Drug Administration. This combination of financial support, research infrastructure, and rigorous regulatory requirements secures the region's dominance in the sector.

Recent Developments

• In January 2025, Quantum-Si Incorporated launched Platinum Pro, its latest benchtop sequencing instrument designed to enhance protein analysis workflows. This new system was introduced to provide researchers with a more efficient and versatile solution for next-generation protein sequencing, building upon the capabilities of the company's original platform. The launch focused on delivering a comprehensive, integrated workflow that streamlines the sequencing process for academic and biopharmaceutical laboratories. By prioritizing accessibility and deeper analytical insights, the company aimed to set a new standard in the field of proteomics and accelerate breakthrough discoveries in biological research.
• In January 2025, Thermo Fisher Scientific announced a significant collaboration with the UK Biobank, which selected the Olink Explore Platform to support a large-scale human proteomics study. This initiative aims to analyze plasma samples from 600,000 participants to identify protein biomarkers associated with disease progression and therapeutic response. The project represents a major advancement in utilizing high-throughput protein measurement technologies to map disease mechanisms at an unprecedented scale. By leveraging this next-generation proteomics solution, the partnership intends to fuel the discovery of novel targets for drug development and improve precision medicine outcomes.
• In October 2024, Bruker Corporation introduced novel methods for deep, high-accuracy plasma proteomics, achieving a cost-efficiency milestone described as the "One-Hundred Dollar Plasma Proteome." Using its timsTOF sequencing technology, the company demonstrated the ability to identify proteins with high specificity and throughput, enabling unbiased profiling of the plasma proteome at scale. This development included advancements in glycoproteomics and immunopeptidomics, offering researchers enhanced tools to study post-translational modifications and protein interactions. The breakthrough was designed to make high-fidelity protein analysis more accessible and affordable for large-scale clinical and translational research studies.
• In January 2024, Alamar Biosciences announced the commercial launch of the ARGO HT System and the NULISAseq Inflammation Panel 250, marking a key expansion in its precision proteomics portfolio. The new system was designed to provide an automated, high-sensitivity solution for detecting proteins in biofluids, significantly reducing the hands-on time required for complex assays. By utilizing its proprietary NULISA technology, the company aimed to offer superior signal-to-noise ratios and the ability to detect low-abundance biomarkers critical for understanding immune responses. This product launch addressed a growing market need for robust, push-button technologies capable of performing multiplexed protein analysis in clinical and research settings.

Key Market Players

• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• Agilent Technologies, Inc.
• Rapid Novor, Inc.
• Charles River Laboratories
• Proteome Factory AG
• Selvita
• Bioinformatics Solutions Inc.
• Creative Proteomics
• Alphalyse

By Product & Service	By Application	By End Use	By Region
Protein Sequencing Products Reagents & Consumables Instruments Software Protein Sequencing Services	Bio-therapeutics Genetic Engineering Others	Academic Institutes & Research Centers Pharmaceutical & Biotechnology Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Protein Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Protein Sequencing Market, By Product & Service:

• Protein Sequencing Products
• Reagents & Consumables
• Instruments
• Software
• Protein Sequencing Services

• Protein Sequencing Market, By Application:

• Bio-therapeutics
• Genetic Engineering
• Others

• Protein Sequencing Market, By End Use:

• Academic Institutes & Research Centers
• Pharmaceutical & Biotechnology
• Others

• Protein Sequencing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE